ArticleBreast cancer research : BCR2026

Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression.

Pratyusha Ghanta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.